9 August 2018 - NICE has reversed its draft decision rejecting Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia, meaning the drug will now be available on the NHS in England and Wales.

The move follows a successful appeal by Pfizer against the Institute’s decision to reject Besponsa as a treatment for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.

Besponsa is an antibody drug conjugate comprised of a monoclonal antibody targeting CD22, a cell surface antigen expressed on around 90% of B-cell malignancies, linked to a cytotoxic agent.

Read Pharma Times article